NCT07098364
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +20 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Clinical trial condition
Refractory Grade 3b Follicular Lymphoma
Explore clinical trials studying Refractory Grade 3b Follicular Lymphoma. Study availability and eligibility vary by location and protocol.
10 public trials
6 recruiting studies
Refractory Grade 3b Follicular Lymphoma trial results
NCT05672251
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +20 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
Recruiting
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
NCT05077527
- Conditions
- AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, Blood-Borne Infections, +36 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- University of Illinois at Chicago Chicago, Illinois, United States
- Memorial Sloan Kettering Cancer Center New York, United States
- Montefiore Medical Center - Moses Campus The Bronx, New York, United States
NCT06536049
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +22 more
- Locations
-
- University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
NCT06784726
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +20 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT06834373
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +39 more
- Locations
-
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Mayo Clinic Health System in Albert Lea Albert Lea, Minnesota, United States
- Mayo Clinic Health Systems-Mankato Mankato, Minnesota, United States
Active, Not Recruiting
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
NCT05821088
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +30 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, Not Recruiting
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT05507541
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +36 more
- Locations
-
- University of Iowa Iowa City, Iowa, United States
- Mayo Clinic Rochester, Minnesota, United States
Active, Not Recruiting
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
NCT05359211
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +17 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Active, Not Recruiting
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
NCT05025800
- Conditions
- Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, +31 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States